Activity-generating delivery molecules comprising the structure R.sup.3—(C═O)-Xaa-NH—R.sup.4 wherein Xaa is any D- or L-amino acid residue with a non-hydrogen, substituted or unsubstituted side chain, R.sup.3—(C═O)— and —NH—R.sup.4 are independently a long chain group, each long chain group containing one or more carbon-carbon double bonds, and salts, compositions and methods of use thereof. The activity-generating delivery compounds and compositions are useful for generating activity of an active agent in a cell, tissue, or subject.

Provided herein are compositions with enhanced sweetness or reduced caloric content per weight when compared to the sweetener carbohydrate or sweetener polyol component thereof, and methods for the preparation thereof.

Provided herein are compositions with enhanced sweetness or reduced caloric content per weight when compared to the sweetener carbohydrate or sweetener polyol component thereof, and methods for the preparation thereof.

A direct write dispensing nozzle assembly and method of forming traces and twisted pairs via direct write dispensing. The method includes dispensing conductive material via an inner nozzle so as to form a conductive core. Non-conductive material may be dispensed via a peripheral nozzle surrounding the inner nozzle so as to form a non-conductive casing surrounding the conductive core. The first conductive core and the non-conductive casing may then be deposited on a substrate or other surface. The trace may be positioned on the substrate such that the non-conductive casing contacts a previously deposited trace. An additional conductive core may be dispensed within the non-conductive casing and the direct write dispensing nozzle assembly may be rotated so as to form a twisted pair.

Various organic molecules, ingredients and compositions are prepared from Stevia rebaudiana plant. The compositions can be used as bulking agents, and sweeteners in foods, beverages, cosmetics and pharmaceuticals.

A maytansinoid is covalently linked through a non-cleavable linker to an EGFR antibody that is a full EGFR antagonist, such as cetuximab or panitumumab. The result is an anti-cancer agent having cytotoxicity that is potentiated in cancer cells but not normal cells. This benefit is not seen with EGFR antibodies that are partial antagonists, or with toxins that are not processed by lysosomes.

Provided is a peptide for targeting gastric cancer, a composition for diagnosing radioresponsiveness-dependent gastric cancer using the peptide, and a drug delivery use of the peptide, wherein a functional peptide capable of targeting cancer has been discovered so as to implement personalized diagnosis and treatment for individual patients having cancer, consideration of problems occurring during treatment in which treatment cases of respective patients differ due to different therapeutic responses resulting from genetic differences in the individual patients.

The invention is directed to isomeric mixtures of cyclosporine analogs that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISA.sub.TX247, and derivatives thereof. Mixtures of ISA.sub.TX247 isomers exhibit a combination of enhanced potency and reduced toxicity over the naturally occurring and presently known cyclosporins. ISA.sub.TX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. The ratio of isomers in a mixture comprises greater than about 80 percent by weight of the E-isomer and less than about 20 percent by weight of the Z-isomer, based on the total weight of the mixture.

Disclosed are synthetic nanocarrier compositions with coupled adjuvant compositions as well as related methods.

A pharmaceutical composition which is Rapidly Dissolved in a mouth, comprising (a) agglomerate units which is consisted of a discontinuous phase comprising the first component; and a continuous phase comprising the second component; and (b) a pharmaceutically acceptable excipient, in which the pharmaceutical composition is characterized in that the first component is an effective ingredient exhibiting the pharmacological activity, and the second component is sugar or sugar alcohol is provided.